HTFLHeartflow, Inc.

$48.89

Price

$48.89
1M+99%1Y-

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier
10/10
Value89
Quality45
Momentum87
Growth81
Strongest Value, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD.

In the company’s own words · 10-K filed Mar 18, 2026 · SEC EDGAR

P/E (TTM)-
Market Cap$2.90B
1Y Return-
5Y Return-

Business segments

Q3 2025 · $46.3M

The company’s own SEC segment disclosure.

  • US$42.9M93%
  • GB$1.5M3%
  • JP$1.5M3%
  • Rest Of Europe$349.0K1%

Heartflow, Inc. (HTFL) reported revenue of $64M in Q2 2026 (quarter ended June 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 83% and net loss of $16M. For the full year FY2025, revenue was $176M (+40% year on year) and net income −$117M. Its largest region in 2025-Q3 was US at $43M, 93% of the disclosed total, just ahead of GB at 3.3%.

Raw charts

9 series · TTM

As reported to the SEC, without any scoring.